Previous 10 | Next 10 |
NantKwest (NK), up 21% premarket and privately-held ImmunityBio and NantKwest (NK) have entered into an agreement to merge in a stock-for-stock transaction. The combination will create an immunotherapy and cell therapy company focused on oncology and infectious disease. Together, Im...
QUILT 3.032 study completes planned enrollment of BCG unresponsive non-muscle invasive bladder cancer CIS cohort with 59% probability of patients maintaining complete response for at least 12 months Over 85% of patients in this study have avoided a cystectomy to date Break...
Merged entity brings together 11 Phase II / III clinical trials across oncology and infectious disease that use combined immunotherapy platforms Broad late-stage pipeline for solid tumors including bladder, lung, breast, and pancreatic in addition to infectious disease p...
Gainers: Sonoma Pharmaceuticals (SNOA) +114%. NantHealth (NH) +110%. vTv Therapeutics (VTVT) +59%. aTyr Pharma (LIFE) +33%. NantKwest (NK) +22%.Losers: SELLAS Life Sciences (SLS) -33%. Immutep (IMMP) -29%. Salarius Pharmaceuticals (SLRX) -29%. Nabriva Therapeutics (NBRV) -29%. ALX O...
NantKwest (NK) rises 16% premarket after its partner ImmunityBio announced results from the Challenge study evaluating, hAd5 T-Cell COVID-19 vaccine candidate.BARDA-sponsored study shows second-generation hAd5 vaccine candidate in both subcutaneous and oral formulations inhibits SARS-CoV...
vTv Therapeutics VTVT +128% as MacAndrews & Forbes buys 625K shares.Sonoma Pharmaceuticals SNOA +122% on Crown Laboratories partnership.FAT Brands FAT +60% on plan to merge with controlling shareholder Fog Cutter Capital.Lexicon Pharmaceuticals LXRX +38%...
BARDA-sponsored study shows second-generation hAd5 vaccine candidate in both subcutaneous and room temperature oral formulations inhibits SARS-CoV-2 virus replication to undetectable levels and clears infection within days in 100% of vaccinated non-human primates The secon...
Gainers: [[NM]] +26.7%. [[QTT]] +4.4%. [[RMG]] +3.6%. [[DXYN]] +3.6%. [[WES]] +1.9%.Losers: [[YJ]] -4.2%. [[NK]] -3.3%. [[LOMA]] -3%. [[EDIT]] -2.3%. [[TRVG]] -2%. For further details see: EDIT, WES, NM and TRVG among after-hours movers
N-803 Boosts CD34+ Progenitor-Derived NK Cell Expansion and Functionality Adding N-803 to NK Cell Therapy has Potential to Improve Cancer Immunotherapy ImmunityBio, a privately-held immunotherapy company, today announced the publication in Cancer Immunology, Immunoth...
Listen on the go! A daily podcast of Wall Street Breakfast will be available by 8:00 a.m. on Seeking Alpha, iTunes, Stitcher and Spotify. Economic reports in the week aheadThe week ahead will see investors once again weigh the brightening prospects for COVID-19 vaccines against a surging pand...
News, Short Squeeze, Breakout and More Instantly...
NantKwest Company Name:
NK Stock Symbol:
NASDAQ Market:
Imerys Enters Long-Term Partnership with TotalEnergies for Renewable Power at its Santa Barbara County Facility PR Newswire A TotalEnergies solar and battery storage solution to bring 130-year-old Lompoc industrial site into new era of sustainability and smart energy manag...
Creates Leading Immunotherapy and Cell Therapy Company ImmunityBio , Inc. and NantKwest , Inc. ( NASDAQ: NK ), today announced the completion of their previously announced 100% stock-for-stock merger. This follows the satisfaction of all customary closing conditi...
NantKwest, Inc . ( NASDAQ: NK ), a clinical-stage, natural killer cell-based therapeutics company, today announced that its stockholders approved by the required vote each of the proposals related to the pending merger of NantKwest and ImmunityBio, Inc. presented at the special ...